Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Pharmaceutical manufacturers have raised the sticker prices on hundreds of drugs at the start of 2020, with most of the increases coming under 10%.

The big picture: It may be a new year, but the same drugs are once again subject to the same industry practices.

Between the lines: Political pressure has forced some drugmakers to consider fewer price hikes on their medicines or to keep the increases in single-digit percentages.

  • Raising prices doesn't necessarily mean net drug spending (after rebates and other discounts given to health insurers) goes up — but it usually does, and many drug price increases aren't justifiable.
  • The price increases are salt in the wound following Congress' failure to pass meaningful drug price legislation in 2019, and are already being used to make the political case for action this year.

By the numbers: As of Friday, drug companies had increased the prices of 445 products by a median of 5%, according to an analysis by 3 Axis Advisors. More hikes are expected throughout January.

  • Pfizer increased the prices of 58 drugs, the most of any company by far. Novartis, Allergan and GlaxoSmithKline each had counts in the twenties.

What we're seeing: Some of the biggest pharmaceutical companies are bumping up prices on popular brand-name drugs, according to pharmaceutical industry analyses from several investment firms and consulting firm 3 Axis Advisors.

  • AbbVie: ⬆️ 7.4% on Humira, the world's top-selling drug that is facing major competition and lower prices everywhere — except the U.S.
  • Biogen: ⬆️ 6% on Tecfidera, a multiple sclerosis drug that is facing a major patent lawsuit.
  • Bristol-Myers Squibb: ⬆️ 6% on blood thinner Eliquis and ⬆️ 1.5% on Opdivo, an outpatient cancer drug that usually doesn't have rebates.
  • Celgene: ⬆️ 6% on cancer treatment Revlimid, which is now owned by Bristol-Myers Squibb.
  • Gilead: ⬆️ 4.8% on a host of medicines, including its main HIV drugs (Truvada, Descovy and Biktarvy).
  • Merck: ⬆️ 1.5% on Keytruda, its blockbuster cancer infusion drug that competes with Opdivo and similarly doesn't usually give back rebates.
  • Novartis: ⬆️ 7% on Cosentyx, a major psoriasis treatment.
  • Pfizer: ⬆️ 5% on breast cancer pill Ibrance and ⬆️ 7.3% on Prevnar, a vaccine that is the company's best-selling drug.
  • Purdue Pharma: ⬆️ 5% on its OxyContin painkiller, all while the company sits in bankruptcy court and the Sackler owners dangle billions in public settlement funds.

Yes, but: List prices don't reflect discounts and rebates, which reduce net prices. List prices do, however, affect people who have high deductibles or are uninsured.

Looking ahead: Amgen, Eli Lilly and other companies haven't released any drug price increases yet, usually waiting until a few days or weeks after the start of the new year.

The bottom line: Congress these days is much better at doing nothing than passing legislation, and its inertia is only going to be made worse by the November election. Until something changes, expect increases to happen again.

Go deeper: Drug makers still raising prices, but seeking fewer hikes

Go deeper

Updated 15 mins ago - Sports

Live updates: Olympics formally kick off with "sobering" opening ceremony

Naomi Osaka lights the Olympic cauldron. Photo: Maddie Meyer/Getty Images

After a year-long delay, the Tokyo Olympics are finally underway. But this year's largely spectator-less opening ceremony is a "sobering" event focused primarily on the athletes.

The latest: The cauldron in Tokyo has been lit, formally kicking off the Olympic Games. Tennis star Naomi Osaka had the honor of carrying the Olympic torch to light the cauldron.

1 hour ago - Sports

Cleveland Indians change name to "Guardians"

The Cleveland Indians baseball team announced Friday that it will change its nickname to the "Guardians," following years of activism and protests against a moniker considered offensive by many Native Americans.

Why it matters: It's the first time the team will change its name since 1915, a move that comes in the wake of the nationwide racial reckoning that began with the murder of George Floyd.

Alabama governor: "It’s time to start blaming the unvaccinated folks"

Photo: Michael Wade/Icon Sportswire via Getty Images

A frustrated Alabama Gov. Kay Ivey (R) told reporters Thursday that "it's time to start blaming the unvaccinated folks, not the regular folks" for the state's continued surge in new COVID-19 cases.

Why it matters: Alabama has reported nearly 8,000 new cases of COVID-19 over the past week. It's one of the few states in the country with fewer than 40% of residents fully vaccinated against COVID-19.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!